CA3234321A1 - Lipid nanoparticles used to transport nucleic acids into lymphatic endothelium cells - Google Patents
Lipid nanoparticles used to transport nucleic acids into lymphatic endothelium cells Download PDFInfo
- Publication number
- CA3234321A1 CA3234321A1 CA3234321A CA3234321A CA3234321A1 CA 3234321 A1 CA3234321 A1 CA 3234321A1 CA 3234321 A CA3234321 A CA 3234321A CA 3234321 A CA3234321 A CA 3234321A CA 3234321 A1 CA3234321 A1 CA 3234321A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- carbon atoms
- lipid
- formula
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021161239 | 2021-09-30 | ||
| JP2021-161239 | 2021-09-30 | ||
| PCT/JP2022/035637 WO2023054242A1 (ja) | 2021-09-30 | 2022-09-26 | 核酸をリンパ管内皮細胞に送達するために用いられる脂質ナノ粒子 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3234321A1 true CA3234321A1 (en) | 2023-04-06 |
Family
ID=85782634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3234321A Pending CA3234321A1 (en) | 2021-09-30 | 2022-09-26 | Lipid nanoparticles used to transport nucleic acids into lymphatic endothelium cells |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250197852A1 (https=) |
| EP (1) | EP4410276A4 (https=) |
| JP (1) | JPWO2023054242A1 (https=) |
| CN (1) | CN118251212A (https=) |
| CA (1) | CA3234321A1 (https=) |
| WO (1) | WO2023054242A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4501361A4 (en) * | 2022-03-28 | 2026-01-28 | Nof Corp | Lipid nanoparticles for delivering nucleic acid to peripheral blood mononuclear cells, and a method for delivering nucleic acid to peripheral blood mononuclear cells using them |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019188867A1 (ja) | 2018-03-27 | 2019-10-03 | 日油株式会社 | 細胞内動態を改善した新規カチオン性脂質 |
| EP3906039A4 (en) * | 2019-01-04 | 2023-01-18 | Oncorus, Inc. | ENCAPSULATED POLYNUCLEOTIDES AND METHODS OF USE |
| WO2020206231A1 (en) * | 2019-04-05 | 2020-10-08 | Precision Biosciences, Inc. | Methods of preparing populations of genetically-modified immune cells |
| JP7700101B2 (ja) * | 2019-09-06 | 2025-06-30 | ジェネレーション バイオ カンパニー | 閉端dnaおよび切断可能脂質を含む脂質ナノ粒子組成物ならびにそれらの使用方法 |
| WO2021060440A1 (ja) * | 2019-09-26 | 2021-04-01 | 日油株式会社 | 脂質ナノ粒子の凍結乾燥組成物 |
| IL296763B2 (en) * | 2020-03-27 | 2026-04-01 | Generation Bio Co | New lipids and their nanoparticle compositions |
-
2022
- 2022-09-26 WO PCT/JP2022/035637 patent/WO2023054242A1/ja not_active Ceased
- 2022-09-26 JP JP2023551463A patent/JPWO2023054242A1/ja active Pending
- 2022-09-26 CN CN202280066444.8A patent/CN118251212A/zh active Pending
- 2022-09-26 EP EP22876109.4A patent/EP4410276A4/en active Pending
- 2022-09-26 CA CA3234321A patent/CA3234321A1/en active Pending
- 2022-09-26 US US18/697,239 patent/US20250197852A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250197852A1 (en) | 2025-06-19 |
| JPWO2023054242A1 (https=) | 2023-04-06 |
| WO2023054242A1 (ja) | 2023-04-06 |
| EP4410276A1 (en) | 2024-08-07 |
| EP4410276A4 (en) | 2025-10-22 |
| CN118251212A (zh) | 2024-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102674501B1 (ko) | 세포 내 동태를 개선한 신규 양이온성 지질 | |
| JP6640750B2 (ja) | カチオン性脂質 | |
| EP4035686A1 (en) | Lipid nanoparticle lyophilized composition | |
| AU710170B2 (en) | Cationic virosomes as transfer system for genetic material | |
| JP2002521423A (ja) | 遺伝子又は薬物運搬体としての脂質エマルジョン及び固形脂質微粒子 | |
| EP4501360A1 (en) | Lipid nanoparticles for delivering nucleic acid to splenic tissue, and method for delivering nucleic acid to splenic tissue using same | |
| Yang et al. | Dual-targeted lipid nanoparticles system for synergistic anti-inflammation and cartilage repair in the treatment of temporomandibular joint osteoarthritis | |
| US20250057977A1 (en) | Lipid nanoparticles having cell directivity | |
| EP4410276A1 (en) | Lipid nanoparticles used to transport nucleic acids into lymphatic endothelium cells | |
| EP4410275A1 (en) | Lipid nanoparticle used for delivering nucleic acid to brain tissue | |
| WO1999021533A2 (en) | Delivery vehicles for bioactive agents and uses thereof | |
| US20260115316A1 (en) | Lipid nanoparticles for delivering nucleic acid to splenic tissue, and method for delivering nucleic acid to splenic tissue using same | |
| EP4555999A1 (en) | Lipid nanoparticle and method for producing same, nucleic acid-encapsulated lipid nanoparticle and method for producing same, and method for inducing acquired immunity in living body by using nucleic acid-encapsulated lipid nanoparticle | |
| EP4691476A1 (en) | Method for producing nucleic acid-encapsulated lipid nanoparticles | |
| EP4501361A1 (en) | Lipid nanoparticles for delivering nucleic acid to peripheral blood mononuclear cells, and method for delivering nucleic acid to peripheral blood mononuclear cells using same | |
| CA3287902A1 (en) | Method for producing nucleic acid-encapsulated lipid nanoparticles | |
| Düzgünes et al. | Intracellular delivery of therapeutic oligonucleotides in pH-sensitive and cationic liposomes | |
| WO2025063214A1 (ja) | 核酸を内封したリガンド修飾脂質ナノ粒子の製造方法 | |
| Zhao | Non-Viral Intracellular mRNA Delivery to Hard-To-Transfect Cells Using Synthetic Lipidoid Nanoparticles | |
| KR101671864B1 (ko) | 요오드화 오일을 함유하는 양이온성 에멀젼 및 바이러스 벡터의 유전자 전달 증진을 위한 이의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240726 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240726 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250730 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250730 |